HVTN 122/gp145 C.6980
Status:Completed
Phase:I
Principal Investigator(s):Katharine Bar, Hong Van Tieu
Objective:The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.Last updated January 31, 2022
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT03382418
Trial Sponsors:
NIAID (DAIDS-ES: 12030)
Start Date
End Date
December 27, 2017
September 25, 2019
Enrollment:45
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women